The non-invasive prenatal testing market size is expected to reach USD 11.39 billion by 2034, exhibiting a CAGR of 9.8% from 2025 to 2034.
The Non-Invasive Prenatal Testing (NIPT) Market represents a transformative segment of the prenatal diagnostics industry. NIPT uses advanced sequencing technologies to screen for chromosomal abnormalities in a fetus by analyzing cell-free fetal DNA in the maternal bloodstream. This test is non-invasive, posing no risk to the fetus, and provides highly accurate results.
Market Growth Drivers
- Increasing Maternal Age
Advanced maternal age is associated with a higher risk of chromosomal abnormalities, driving the adoption of NIPT among expectant parents. - Growing Awareness of Prenatal Care
Rising awareness about genetic disorders and the benefits of early screening is boosting demand for non-invasive diagnostic solutions. - Technological Advancements
Innovations in next-generation sequencing (NGS) and bioinformatics have improved the accuracy, affordability, and accessibility of NIPT.
Download Free Sample PDF Copy of the Report:
List of Key Companies in Non-Invasive Prenatal Testing (NIPT) Market
- Agilent Technologies, Inc.
- Centogene N.V.
- Eurofins LifeCodexx GmbH
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Laboratory Corp. of America Holdings
- MedGenome Labs Ltd.
- Myriad Women’s Health, Inc.
Key Trends
- Integration with Artificial Intelligence (AI)
AI-powered algorithms are being used to enhance data analysis, improving test accuracy and efficiency. - Expansion of Test Panels
NIPT providers are expanding their offerings to include screening for microdeletions, monogenic disorders, and other rare conditions. - Home-Based Testing Options
The COVID-19 pandemic accelerated the adoption of home sample collection services for NIPT, a trend that continues to grow.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
By Gestation Period Outlook (Revenue – USD Billion, 2020–2034)
- 0-12 weeks
- 13-24 weeks
- 25-36 weeks
By Component Outlook (Revenue – USD Billion, 2020–2034)
- Consumables
- Instruments
- Software
- Services
By Method Outlook (Revenue – USD Billion, 2020–2034)
- Cell-Free DNA in Maternal Plasma Tests
- Ultrasound Detection
- Biochemical Screening Tests
- Others
By Application Outlook (Revenue – USD Billion, 2020–2034)
- Monosomy
- Trisomy
- Microdeletion Syndrome
- Others
By End Use Outlook (Revenue – USD Billion, 2020–2034)
- Diagnostic Centers
- Hospitals and Clinics
- Others
Non-Invasive Prenatal Testing Market Developments
September 2023: Yourgene Health announced the launch of MagBench Automated DNA kits and extraction for NIPT workflow. This integrated solution has enabled clinical laboratories to offer accurate and competitive non-invasive prenatal testing (NIPT) services, ensuring streamlined processes from sample collection to result generation.
September 2022: Eurofins Genoma, announced the launch of niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. The goal of niPGT-A is to offer IVF facilities a precise substitute for conventional testing while also fulfilling the many diagnostic requirements related to reproductive genetics.
August 202: Natera, Inc. declared that, as part of the Q-Sub procedure, the company has filed a pre-submission to the FDA for its non-invasive prenatal test (NIPT), called Panorama.
May 2021: Illumina, Inc. and Next Generation Genomic Co., Ltd. partnered to announce the launch of VeriSeq NIPT Solution v2 in Thailand. It is a next-generation sequencing (NGS)-based approach for noninvasive prenatal testing (NIPT).
The Non-Invasive Prenatal Testing (NIPT) Market is reshaping prenatal care by offering safer, more accurate, and earlier detection of genetic abnormalities. As technology advances and awareness grows, the market is poised for significant expansion. Addressing challenges such as cost and accessibility will be key to ensuring that the benefits of NIPT reach a wider audience, ultimately improving maternal and fetal health outcomes worldwide.